These organizations agree to develop international cooperation on using proteomic methods to characterize tumors and compare findings to other diagnostic features including genomic characterization. The motivation for these MOUs is to gain a deeper understanding of cancer at the molecular level, identify targets and pathways of therapeutic intervention, share knowledge and experience in support each other's endeavors in proteogenomics science, and promote the development and adoption of standards in basic and clinical medicine.